PolyNovo Revenue and Competitors
Estimated Revenue & Valuation
- PolyNovo's estimated annual revenue is currently $74M per year.
- PolyNovo's estimated revenue per employee is $251,000
Employee Data
- PolyNovo has 295 Employees.
- PolyNovo grew their employee count by 30% last year.
PolyNovo Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $17.1M | 68 | -4% | N/A | N/A |
#2 | $26.9M | 107 | 8% | N/A | N/A |
#3 | $24.8M | 99 | 5% | N/A | N/A |
#4 | $19.1M | 76 | 0% | N/A | N/A |
#5 | $30.4M | 121 | 4% | N/A | N/A |
#6 | $74.3M | 296 | N/A | N/A | N/A |
#7 | $40.2M | 160 | 5% | N/A | N/A |
#8 | $74M | 295 | 30% | N/A | N/A |
#9 | $420.2M | 1674 | 8% | N/A | N/A |
#10 | $51.5M | 205 | 1% | N/A | N/A |
What Is PolyNovo?
PolyNovo Biomaterials Pty Ltd. is the developer and owner of a unique biodegradable polymer - NovoSorb TM. We are located at 2/320Lorimer St, Port Melbourne, Victoria 3207, Australia. PolyNovo develops Regenerative Devices for reconstructive surgery and tissue repair with our patented biodegradable polymer technology, NovoSorb NovoSorb is a family of medical grade polymers used to form medical devices to reconstruct or repair failed tissue. NovoSorb can be tailored to a desired strength, elasticity or degradation profile. NovoSorb has significant advantages in terms of safety, toxicology profile and strength. PolyNovo will access the market through strategic partnerships with leaders in targeted segments. Our Polymer can be made into Dermal Matrix, Implantable devices and other regenerative devices. We have TUV SUD certification, ISO 13485. We are listed on the ASX (Australian Securities Exchange) Code: PNV Visit: www.polynovo.com for latest news Biodegradable Polymers, NovoSorb, BTM, NovoPore
keywords:N/A
N/A
Total Funding
295
Number of Employees
$74M
Revenue (est)
30%
Employee Growth %
N/A
Valuation
N/A
Accelerator
PolyNovo News
How much would your initial investment be worth now? If you'd invested $5,000 into Polynovo shares in 2017, you would have picked them up for...
That may have helped boost Polynovo's shares at specific points throughout March. Additionally, brokers have been bullish on the stock lately.
Medical device company PolyNovo (PNV) achieves a record unaudited revenue total of $12.26 million for the March 2022 quarter,...
Other Companies in Port Melbourne
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $102.2M | 327 | 4% | N/A |
#2 | $122.5M | 338 | -20% | N/A |
#3 | $15M | 353 | 5% | N/A |
#4 | $114.2M | 364 | -1% | N/A |
#5 | $15M | 609 | N/A | N/A |